Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Review Question - QID 217221

In scope icon M 3
QID 217221 (Type "217221" in App Search)
A 71-year-old man with a history of human immunodeficiency virus (HIV) infection presents to his primary care physician for follow-up 3 months after starting a new medication regimen. His previous medications were no longer covered by his insurance, so one of the components of his therapy was switched at the previous visit. His past medical history is also significant for atrial fibrillation for which he has taken a stable dose of warfarin for years. He has no history of diabetes, hyperlipidemia, or hypertension. Selected interval laboratory results since switching his medication are shown below:

Fasting serum:
Glucose: 171 mg/dL
Triglycerides: 221 mg/dL

Coagulation studies:
International normalized ratio (INR): 3.8

Which of the following medications was most likely started in this patient?

Efavirenz

0%

0/0

Indinavir

0%

0/0

Maraviroc

0%

0/0

Raltegravir

0%

0/0

Zidovudine

0%

0/0

Select Answer to see Preferred Response

bookmode logo Review TC In New Tab

This patient who presents with hyperglycemia, hyperlipidemia, and inhibition of cytochrome P450 activity (as seen with an elevated INR in the setting of use of warfarin, a P450 substrate) after starting a new HIV medication was most likely started on a protease inhibitor such as indinavir.

Protease inhibitors are an important class of medications that are used in the treatment of HIV. They are most commonly used as part of highly active antiretroviral therapy regimens. Important side effects of protease inhibitors include hyperglycemia, gastrointestinal upset, acute pancreatitis, and fat redistribution/lipodystrophy. Indinavir-specific side effects include nephropathy, kidney stones, hematuria, and thrombocytopenia. In addition, protease inhibitors have significant drug metabolism interactions because they are all CYP450 inhibitors that decrease the metabolism of other CYP450-dependant medications such as warfarin.

Ismail et al. studied the mechanisms by which protease inhibitors lead to hyperglycemia and hyperlipidemia. They found that the insulin resistance induced by these medications is mediated by the NF-kB pathway.

Incorrect Answers:
Answer 1: Efavirenz is a non-nucleoside reverse transcriptase inhibitor that can also be used in the treatment of HIV; however, this drug is an inducer of the P450 system and is associated with the side effects of vivid dreams, confusion, and headaches.

Answer 3: Maraviroc is a fusion inhibitor that can also be used in the treatment of HIV; however, this drug is associated with the side effect of hepatotoxicity and increased serum AST and ALT levels.

Answer 4: Raltegravir is an integrase inhibitor that can also be used in the treatment of HIV; however, this drug is associated with the side effect of myalgias and increased serum creatine kinase levels.

Answer 5: Zidovudine is a nucleoside reverse transcriptase inhibitor that can also be used in the treatment of HIV; however, this drug is associated with the side effect of pancreatitis.

Bullet Summary:
Protease inhibitors have the side effects of hyperlipidemia, hyperglycemia, and inhibition of cytochrome P450 activity.

REFERENCES (1)
Authors
Rating
Please Rate Question Quality

0.0

  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon

(0)

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options